CureVac NV logo

5CV - CureVac NV News Story

€38.63 1.9  5.2%

Last Trade - 3:36pm

Sector
Healthcare
Size
Large Cap
Market Cap £5.74bn
Enterprise Value £4.66bn
Revenue £41.6m
Position in Universe 168th / 1048

UPDATE 1-European regulator says more data needed on Sputnik, Sinovac vaccines

Thu 9th September, 2021 1:01pm
(Adds quote)
    FRANKFURT, Sept 9 (Reuters) - The European Union's drugs
regulator said it was awaiting more data on Russia's Sputnik V
and a rival COVID-19 vaccine by China's Sinovac Biotech  SVA.O 
before it can progress on its rolling reviews of the two shots.
    "For these vaccines the discussion with the companies has
been quite constructive but it looks like there are more data
that need to be submitted to us before we can progress with the
different rolling reviews," the European Medicines Agency's
(EMA) head vaccines strategy, Marco Cavaleri, told a press
briefing.
    He added EMA would continue to review data on German biotech
firm CureVac's  5CV.DE  shot over the next few weeks before a
conclusion can be drawn.
    Commenting on EMA's fourth ongoing rolling review, of a shot
developed by U.S. firm Novavax  NVAX.O , he said its
manufacturing would be discussed further over the next few weeks
and an overall conclusion of the review is possible before
year-end.    



 (Reporting by Ludwig Burger and Pushkala Aripaka; Editing by
Jon Boyle)
 ((ludwig.burger@thomsonreuters.com; +49 30 220133634; Reuters
Messaging: ludwig.burger.thomsonreuters.com@reuters.net))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.